Kirby Daniel Gordon 4

What Happened
Daniel Gordon, Chief Commercial Officer of Iovance Biotherapeutics (IOVA), received an award of 132,200 restricted stock units (RSUs) on March 9, 2026. The grant is reported as a derivative award at $0.00 per unit (no cash paid at grant). Each RSU is a contingent right to one share of common stock that will convert into shares if and when the units vest.

Key Details

• Transaction date: 2026-03-09; filing date: 2026-03-11.
• Award: 132,200 RSUs granted, reported at $0.00 per unit (derivative award).
• Vesting: RSUs vest over three years — one-third on the one-year anniversary, then the remaining two-thirds in eight equal quarterly installments over the following two years, subject to continued employment.
• Shares owned after transaction: not disclosed in the Form 4 provided.
• No tax withholding, sale, or exercise reported in this filing; this is a compensation grant (code A).

Context
RSU grants are common executive compensation and do not involve an immediate market purchase or sale; they become actual shares only as they vest. Such awards are typically retention/compensation-related and do not, by themselves, indicate insider buying or selling sentiment.